Introduction
Tracheal intubation is a common procedure in critically ill patients (1) . Despite its frequent occurrence, tracheal intubation in this setting remains a risky procedure (2, 3) , mainly due to the combination of two synergistic and negative factors: the unique respiratory and hemodynamic instability of critically ill patients, and the high incidence of difficult airway in this population (4) . Intubation-related life-threatening hypoxemia, hypotension, arrythmia, cardiac arrest and death are frequently reported (2, 3) . Recently, a multicenter retrospective trial on tracheal intubation in Intensive Care Unit (ICU) observed a 2.7% rate of cardiac arrest (strongly predicted by hypoxemia prior to intubation and lack of preoxygenation), with a high 28-day mortality in patients who had experienced an intubation-related cardiac arrest (5) .
Given this premise, it is not surprising that a strong effort to improve our daily practice is ongoing, including a growing number of randomized trials, the proposal of bundles, the publication of expert opinions, systematic review and guidelines (4, (6) (7) (8) (9) (10) . Unfortunately, findings from trials evaluating single interventions or bundles are often contradictory and overall insufficient to identify and recommend the best protocol (10): more research is urgently needed and every new trial on this topic is warmly welcome.
High-flow nasal oxygen for preoxygenation
Preoxygenation techniques aim to stock as much oxygen as possible in the patient's blood lungs in the few minutes (or seconds, in emergency scenarios) before attempting intubation, to increase the safety of the procedure by preventing or minimizing hypoxemia during the apneic phase. When time permits, preoxygenation is a key intervention and is considered mandatory by guidelines (4): however, the same guidelines warn that operating room standard techniques can be ineffective in critically ill ICU
patients.
High-flow nasal oxygen (HFNO), consisting in the delivery of high flow rates (up to 60 L/min) of heated and humidified oxygen through the nostrils, has been proposed to treat hypoxemic acute respiratory failure (11) . The potential preoxygenation benefits of HFNO, often including the application also during the apneic phase ("apneic oxygenation") was evaluated in several trials and meta-analysis (10): limited evidence based on five trials suggested that HFNO applied for apneic oxygenation does not reduce the rate of severe hypoxemic events, but might improve the peri-procedural lowest oxygen saturation without reducing the rate of severe hypoxemic events (10) . Several reasons could explain the limited efficacy of HFNO, particularly in patients breathing through the mouth. This prevents an improvement in lung volume and an increase in lung oxygen reserve (12) .
Recently a multicenter, randomized trial focused on intubation of non-severely hypoxemic critically ill adult patients, excluding patients with a pO 2 /FiO 2 ratio below 200 mmHg and comparing HFNO (pure oxygen, with flow set at 60 L/min) to standard bag-valve mask oxygenation (SMO, oxygen flow 15 L/min by a self-inflating resuscitator with reservoir, manually and firmly held in place) (13) . The study took place in seven French ICUs; preoxygenation lasted 4 minutes in both groups, but HFNO was maintained also during intubation to offer an apneic oxygenation. The administered drugs were not standardized. The trial enrolled 184 patients, while 922 assessed for eligibility were excluded. Most patients were intubated for neurological reasons.
The primary outcome was the median lowest SpO 2 during the intubation (from laryngoscopy until connection to the ventilator): no significant difference was observed between groups.
Secondary outcomes included several minor and major endpoints, like predefined moderate or severe adverse events, time on ventilation, organ failure during the first 5 days, length of stay in ICU, incidence of ventilator associated pneumonia, and mortality rate at day 28. The average time to intubation was significantly longer in the HFNO group (1 vs. 0.8 min) and the incidence of difficult intubation was higher with HFNC (10% vs. 1%). Despite this, significantly more patients in the SMO group experienced drops in SpO 2 : 23% in SMO group vs. 12% in HFNO group experienced a drop of SpO 2 below 95%, 14% vs. 6% of patients experienced a drop below 90% (P=0.1) and 2% vs. 8% of patients showed values of SpO 2 below 80% (P=0.06). Overall, a significant higher incidence of severe adverse events was observed in the SMO group (16% vs. 6%); the same was true for moderate complications. The multivariate analysis confirmed the association of HFNO with less desaturation episodes below 90% (OR 0.21 vs. SMO) and with less intubation-related complications (OR 0.26). The Authors concluded that HFNO was associated with improved safety during intubation of non-severely hypoxemic critically ill patients, likely secondary to an apneic oxygenation effect.
Previously, the same research group had published a similar study but focusing on hypoxemic ICU patients, evaluating HFNO for preoxygenation versus high fractioninspired oxygen facial mask in adult patients with a pO 2 /FiO 2 ratio <300 mmHg: no difference in any outcome was observed. Of note, at least one severe complication occurred in majority of patients (14) .
New insights on HFNO and preoxygenation
Before the study by Guitton (13) , according to guidelines and meta-analysis HFNO resulted to offer no relevant benefit but also no harm (4, 10) . In contrast, a very recent retrospective trial reported negative outcomes with HFNO (15) . In a secondary analysis of the MACMAN trial on videolaryngoscope versus Macintosh laryngoscope, the Authors evaluated the efficacy of the four techniques applied for preoxygenation in adult ICU patients: bag-valve mask (BVM), non-rebreathing mask (NRM), HFNO and noninvasive ventilation (NIV). Two factors resulted associated with drops of SpO 2 below 90%: low baseline SpO 2 and preoxygenation device. Having BVM as reference, NIV significantly reduced the risk of hypoxemia (OR 0.1), NRM was not different from BVM, while HFNO significantly increased the risk (OR 5.75). It should be noted that the average pO 2 /FiO 2 was well below 200 mmHg in all the four groups. The Authors concluded that the role of HFNO remained unclear and might be reserved in patients with mild hypoxemia, while NIV should be considered the first choice in severely-hypoxemic patients.
In a randomized controlled multicenter trial (the FLORALI-2 study) enrolling more than 300 patients, Frat et al. compared HFNO to NIV for preoxygenation (16) . No difference in the rate of severe hypoxemic episodes or of other immediate or late severe complications; however, in the subgroup of patient with a pO 2 /FiO 2 ratio below 200 mmHg at baseline, patients preoxygenated by NIV showed a significant lower incidence of severe hypoxemia (24% vs. 35%).
Finally, another multicenter randomized study recently published offers complementary data on preoxygenation in critically ill adults (6) . Preoxygenation included bag-mask ventilation (BVM, different to bag-valve oxygenation, in which the device is simply maintained on the face of the patient, because ventilation is delivered) and a PEEP of 5-10 cmH 2 O compared to no ventilation (in most cases in this group supplemental oxygen was delivered, by facemask or nasal cannula). In the BVM group the median lowest SpO 2 was significantly higher (a difference more marked in severely hypoxemic patients) and drops of SpO 2 below 80% significantly less numerous (11% vs. 23%). Moreover, the incidence of aspiration was not different. So, BVM appeared safer than no ventilation in terms of hypoxemic adverse events, without an increased risk of aspiration.
A work-in-progress, operative protocol
The study by Guitton and co-workers (13) showed that even the intubation of non-severely hypoxemic ICU patients presents a high incidence of adverse events; on the other hand, the enrolled patients were only a minority of the screened ones, with more patients excluded as they were severely hypoxemic. Hence, a standardized, wellconstructed protocol for tracheal intubation (including the occurrence of difficult airway) should be in place in every ICU and all members of the team should be trained on it (7, 9) . While awaiting the results of future trials, we would offer a tentative summary relative to preoxygenation and apneic oxygenation for everyday practice based on best available evidence, published guidelines and personal experience, also following the ARDS Berlin definition as a pragmatic reference ( Table 1) (4, 6, 10, 15, (17) (18) (19) (20) . The assumption is that there is no best technique to be adopted with every ICU patient; on the contrary, a progressive approach based on the severity of the acute respiratory failure (ARF, considered as the main non-modifiable risk factor for severe adverse event) should be adopted. Of course, safety is never too much and when in doubt one should choose the more prudent technique.
Three elements of the proposed protocol deserve further comments. First, NIV should be considered the gold standard in the worst cases (4, 10, 15, 21) ; at a minimum, it should never be interrupted before intubation if the patient is already on NIV, on the contrary NIV should be optimized for intubation setting FiO 2 at 100%. Second, a single trial suggested that the adjunct of HFNO for apneic oxygenation to NIV may be more beneficial than NIV alone in patients with pO 2 /FiO 2 <300 mmHg (22) . Finally, in extreme cases with pO 2 /FiO 2 <100 mmHg we warmly suggest considering awake fibreoptic intubation without interrupting non-invasive ventilation, through dedicated masks: this technique allows to avoid major sedation and apneic periods, so avoiding or strongly minimizing the synergistic negative effects on hemodynamic and blood oxygenation of sedative agents and apnea. This technique has never been evaluated, but it appears logical and, in our experience, safe even in patients to be intubated for NIV failure (19) .
Conclusions
The study by Guitton and co-workers (13) adds relevant data on the risky issue of intubation of critically ill patients. Even if the last words on HFNO is still to be said and contradictory findings have been reported, Guitton suggests that non-severely hypoxemic ICU patients are at risk for adverse events during intubation and might benefit from HFNO. While awaiting for conclusive results from future trials, a stepwise protocol based on ARF severity could help make the procedure safer.
